Clinical Podcasts

UpToDate faculty discuss important “What’s New” and “Practice Changing UpDates”, based on recent medical journal articles, in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice. Each clinical podcast includes the most current clinical information available as of the release date listed.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

To be alerted as each new episode airs, simply subscribe to our podcast channel on iTunes. Also, check out our Healthcare Industry Podcasts that explore healthcare initiatives with an impact on quality and patient safety. We hope you will find these series an enjoyable way to keep UpToDate!

Investigational gene editing in human embryos to prevent disease; Tests for the diagnosis of influenza

Date Released: Nov 29 2017

This episode features Dr. Benjamin Raby discussing a recent paper on correcting a pathogenic gene mutation in human embryos, and Dr. Martin Hirsch discussing testing for diagnosing influenza. Dr. Nancy Sokol hosts.

Dr. RabyDr. Benjamin Raby is an Associate Professor of Medicine at the Harvard Medical School, a Pulmonologist and a Researcher in Genetics at the Channing Division of Network Medicine.
Dr. HirschDr. Martin Hirsch is a Professor of Medicine at the Harvard Medical School and Senior Physician in Infectious Diseases at the Massachusetts General Hospital in Boston.

Segment on investigational gene editing in human embryos to prevent disease (Dr. Benjamin Raby):

  1. Ma H, Marti-Gutierrez N, Park SW, et al. Correction of a pathogenic gene mutation in human embryos. Nature 2017; 548:413.
  2. Ormond, KE et al. Human Germline genome editing: ASHG Position statement. Am J Hum Genet 2017; 101:167 4. http://retractionwatch.com/2017/10/05/nature-adds-alert-heavily-debated-...

Segment on Tests for the diagnosis of influenza (Dr. Martin Hirsch):

  1. Merckx J, Wali R, Schiller I, et al. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis. Ann Intern Med 2017; 167:394.

Benjamin A Raby, MD, MPH Equity Ownership/Stock Options: CureSpark, Inc [General science]. Employment (spouse): Paraxel [Hematology (CRO)] - No relevant conflict on topic.

Martin S Hirsch, MD Nothing to disclose

Prevention of HIV in high risk adolescents; ICDs for treatment of nonischemic cardiomyopathy

Date Released: Nov 15 2017

This episode features Dr. Kenneth Mayer, discussing use of pre-exposure HIV prophylaxis for high-risk adolescents, and Dr. Samuel Lévy, discussing use of an implantable cardioverter defibrillator for the primary prevention of sudden death in patients with nonischemic cardiomyopathy. Dr. Nancy Sokol hosts.

Dr. MayerDr. Kenneth Mayer is Professor of Medicine at Harvard Medical School and Medical Research Director at Fenway Health in Boston.
Dr. LévyDr. Samuel Lévy is Professor of Cardiology at Aix-Marseille University School of Medicine and Hospital Nord, Marseille, France.

Segment on prevention of HIV infection (Dr. Mayer):

  1. Hosek SG, Landovitz RJ, Kapogiannis B, et al. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatr 2017; 171:1063.

Segment on ICDs for treatment of cardiomyopathy (Dr. Lévy):

  1. Golwala H, Bajaj NS, Arora G, Arora P. Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis. Circulation 2017; 135:201.
  2. Shun-Shin MJ, Zheng SL, Cole GD, et al. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. Eur Heart J 2017; 38:1738.
  3. Stavrakis S, Asad Z, Reynolds D. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Electrophysiol 2017; 28:659.
  4. Kolodziejczak M, Andreotti F, Kowalewski M, et al. Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. Ann Intern Med 2017; 167:103.

Kenneth H Mayer, MD Grant/Research/Clinical Trial Support: Gilead Sciences [PrEP (Tenofovir-emtricitabine)]; ViiV Healthcare [PrEP (Cabotegravir)].

Samuel Lévy, MD Consultant/Advisory Boards: Cardiome Pharma [Chair of the Safety Committee, Spectrum Study (Vernakalant IV)].

Zika virus prenatal infection and birth outcome; Evaluation for occult cancer in unprovoked VTE

Date Released: Nov 1 2017

This episode features Dr. Karin Nielsen discussing maternal Zika virus and potential factors associated with birth outcomes, and Dr. Jess Mandel discussing screening for occult cancer in patients with unprovoked venous thromboembolism.  Dr. Jennifer Mitty hosts.

Dr. NielsenDr. Karin Nielsen is a Clinical Professor of Pediatrics in the Division of Infectious Diseases at the David Geffen School of Medicine at UCLA and UCLA Mattel Children's Hospital. She is also the Director of the Center for Brazilian Studies at UCLA.
Dr. MandelDr. Jess Mandel is Professor of Clinical Medicine and Vice Chair of Education in the Department of Medicine at the University of California, San Diego. He is also Vice Chief of the Division of Pulmonary Critical Care and Sleep Medicine.

Segment on severity of maternal Zika virus infection and birth outcome (Dr. Karin Nielsen):

  1. Halai UA, Nielsen-Saines K, Moreira ML, et al. Maternal Zika Virus Disease Severity, Virus Load, Prior Dengue Antibodies, and Their Relationship to Birth Outcomes. Clin Infect Dis 2017; 65:877.

Segment on evaluation for occult cancer in unprovoked venous thromboembolism (Dr. Jess Mandel):

  1. van Es N, Le Gal G, Otten HM, et al. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis of Individual Patient Data. Ann Intern Med 2017; 167:410.

Karin Nielsen, MD, MPH Nothing to disclose

Jess Mandel, MD Nothing to disclose

Choice of basal insulin for management of diabetes; Evaluation of children with febrile seizures

Date Released: Oct 18 2017

In this episode, Dr. David Nathan discusses choice of basal insulin for management of type 1 and type 2 diabetes, and Dr. Douglas Nordli, Jr., discusses evaluation of children with febrile seizures. Dr. Nancy Sokol hosts.

Dr. NathanDr. David Nathan is a Professor of Medicine at Harvard Medical School and Director of the Diabetes Center at Massachusetts General Hospital in Boston.
Dr. NordliDr. Douglas Nordli is a Professor of Clinical Neurology and Vice Chair of Neurology at the University of Southern California Keck School of Medicine, and Chief of Pediatric Neurology at Children's Hospital Los Angeles.

Segment on empagliflozin (Dr. Nathan):

  1. Lane W, Bailey TS, Gerety G, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA 2017; 318:33.
  2. Wysham C, Bhargava A, Chaykin L, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA 2017; 318:45.

Segment on febrile seizures (Dr. Nordli):

  1. Guedj R, Chappuy H, Titomanlio L, et al. Do All Children Who Present With a Complex Febrile Seizure Need a Lumbar Puncture? Ann Emerg Med 2017; 70:52.

David M Nathan, MD Nothing to disclose

Douglas R Nordli, Jr, MD Nothing to disclose

Pages